To determine the prevalence of HPV types using genotyping in high grade squamous intraepithelial lesion (HSIL)/ adenocarcinoma in situ (AIS)/early-stage invasive cervical cancer (ICC), in patients who have been exposed or naïve to HPV vaccine. This was a cross-sectional study. All patients over the age of 18 presenting to the colposcopy clinic with HSIL, AIS, or ICC who were expected to undergo a cervical biopsy, loop electrosurgical excisional procedure (LEEP), or cone biopsy were eligible and approached for informed consent. HPV typing was performed to identify the causative HPV types. Between November 2016 - May 2023, 113 patients (34 vaccinated with at least 1 dose, and 79 non-vaccinated) were consented to this study. The median ages of coitarche and at study entry were 18 (range 14-37) and 34 (range 24-66), respectively. Only 3 patients were vaccinated prior to coitarche. Histology was as follows: HSIL=97, AIS=9, HSIL and AIS=2, squamous cell carcinoma=4, and 1 patient with adenocarcinoma. Causative HPV was 16 or 18 in 59% of the vaccinated group, and 66% in the non-vaccinated group. Most vaccinated patients (74%) reported receiving 2-3 doses of an HPV vaccine. In our cohort, the distribution of causative HPV 16 and 18 in patients presenting with HSIL/AIS/ICC is similar between vaccine naïve and vaccinated patients. This data suggests cervical screening guidelines should not differentiate between "vaccinated" and "non-vaccinated" women without further details of their vaccination.
Read full abstract